Ian McGowan MD DPhil FRCP University of Pittsburgh Pittsburgh, PA, USA

Slides:



Advertisements
Similar presentations
HIV/AIDS The Epidemic in ANE and E&E So what do we do now? Paul De Lay Senior Advisor on HIV/AIDS Office of HIV/AIDS.
Advertisements

HIV treatment as prevention Stephen Kegg. 2 Learning Outcomes Overview of HIV management HIV transmission risks Current prevention strategies Which new.
Dr. Carol Odula (Obs./Gyn.) May 7 th 2013 Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection.
State of the Field Exploring 2015’s Top Ten List for the HIV Prevention Research Field Manju Chatani, Stacey Hannah, Mitchell Warren Thursday, January.
Maurice Cook ( EM Designs Group, Inc.) The End of AIDS Transmission? Robert M Grant, June 2012.
Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection James Wilton Project Coordinator Biomedical Science of HIV Prevention
HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.
How well are we doing in preventing HIV and how can we do better?
Use of Antivirals in Prevention Oral and Topical Prophylaxis
Dr Himani. Foams or creams that people can use in vagina or rectum during sex to prevent transmission Currently, there is no vaccine to prevent HIV. This.
The 4 th Decade of the HIV Epidemic: Midwest Regional Response September 17, 2013 with Jim Pickett, AFC/IRMA The Bottom Line on Rectal and Vaginal Microbicide.
Jim Pickett, IRMA/AFC GMHC – January 23, 2013 The Bottom Line on Rectal Microbicide Research.
Microbicide Research: A Promising HIV/AIDS Prevention Strategy for Women Roberta Black, Ph.D. Division of AIDS, National Institute of Allergy and Infectious.
Introduction to HIV New Prevention Technologies (NPTs)
Slide 1 of 9 From J Marrazzo, MD, at Los Angeles, CA: April 22, 2013, IAS-USA. IAS–USA Jeanne Marrazzo, MD, MPH Professor of Medicine University of Washington.
Summarising Male Circumcision Efficacy: Results of the three randomised clinical trials Neil A Martinson Perinatal HIV Research Unit.
Prior to exposure Point of transmission After infection Male and female condoms Antiretroviral therapy (mother-to- child) Post exposure prophylaxis (PEP)
XIX International AIDS Conference
Microbicides for HIV Prevention Pamina M. Gorbach, Epidemiology & Infectious Diseases UCLA.
State of Global Rectal Microbicide Research Ian McGowan MD PhD FRCP Magee-Womens Research Institute University of Pittsburgh.
DEVELOPING DUAL COMPARTMENT MPTS THAT WORK UP FRONT AND FROM BEHIND José Fernández Romero Population Council September 9, 2015.
Myron S. Cohen, MD Associate Vice Chancellor Director, Institute for Global Health The University of North Carolina.
Katharine Kripke, Ph.D. Assistant Director, Vaccine Research Program, Division of AIDS, NIAID AIDS Vaccine 2011 Journalist Training Program September 11,
Moving the Rectal Microbicide Agenda Forward; Results from a Scientific, Ethical, and Community Consultative Process Ian McGowan MD PhD FRCP University.
What Is Currently in the Pipeline & What is Ideal for an ARV-based Prevention Candidate? Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID,
When Will Women Have Choices? Sharon Hillier University of Pittsburgh School and Medicine Microbicide Trials Network IAS, Washington DC, July 26, 2012.
The Microbicide Trials Network Group 3 Lindsay O. Bryant Danielle M. Campbell Alan D. Johnson Leroy Smith Jr. Kendra M. Taylor May 31, 2016.
INVESTING TO END THE AIDS EPIDEMIC: A NEW ERA FOR HIV RESEARCH & DEVELOPMENT HIV VACCINES WORKING GROUP & MICROBICIDES RESOURCE TRACKING E. Donaldson 1,
Implications of Anal Intercourse and Rectal use of Products in Vaginal Microbicide Trials Ian McGowan MD PhD FRCP.
Welcome South Africa 4 Rectal Microbicides A Stakeholder Consultation on Rectal Microbicide Research and Advocacy Please sign in.
IAS July 1 The Caprisa 004 result in context Sheena McCormack Clinical Scientist MRC Clinical Trials Unit.
N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Pre-exposure Prophylaxis for HIV Prevention Efficacy and the importance of adherence Joanne Stekler,
Looking Ahead to MTN-017 Ross D. Cranston MD, FRCP Microbicide Trials Network IRMA.
Advances in Biomedical HIV Prevention Interventions
New Prevention Technologies Workshop Module 2: NPTs in context
Antiretrovirals for HIV Prevention: Progress and Challenges Kenneth H. Mayer, M.D. Brown/Miriam/Fenway.
HIV and Women Collaborating Across Borders to Advance the Health of Women IAS 2012 Gina M. Brown, M.D. July 22, 2012.
HVTN 702: A pivotal phase 2b/3 multi-site, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of ALVAC-HIV.
Vaccines and Microbicides Rebekah Webb, AVAC STOPAIDS All Members Meeting: Re-prioritising Prevention London, 12 th May 2016.
Persistence of Rilpivirine Following Single Dose of Long-Acting Injection Ian McGowan MD DPhil FRCP Professor of Medicine, University of Pittsburgh for.
Pre-exposure Prophylaxis (PrEP) for HIV Prevention: What’s the Future? Joanne Stekler, MD MPH Assistant Professor of Medicine University of Washington.
Information about HIV Prevention Options
AVAC IAS Symposium July 23rd, 2017
IAS Satellite Session 25th July 2017 Daniel Were, PhD
Module 4 (e) Pregnancy and Breast Feeding
Presenter ITODO EWAOCHE
What’s Next – and When: An Update on Injectable Prevention
Long Acting Injectable Agents for HIV Prevention
Module 4 (c) Stopping PrEP
Rectal Microbicides: Where We’re Heading
On behalf of The MTN-020/ASPIRE Study Team
MTN-036 Study of Extended Duration Dapivirine Vaginal Ring for HIV Prevention How do I know if I’m Eligible to join? Women who join the study must.
Role of Explant Tissue Infection Assays Ian McGowan MD DPhil FRCP University of Pittsburgh, PA, USA 26th July, Paris, France Wednesday October 7th 15.
MULTIPURPOSE PREVENTION TECHNOLOGY (MPT) PRODUCT PIPELINE & THEIR POTENTIAL ACCEPTABILITY AMONG ADOLESCENT GIRLS & YOUNG WOMEN Barbara Friedland, Population.
Can Pharmacology Help? Peter L. Anderson, Pharm.D.
The HIV Prevention Landscape
Annual Research Day 17 April 2015
Antibody Mediated Prevention: HVTN 703/HPTN 081 Update
The Possibilities of PrEP: Introduction
Setting the Stage for PrEP Where are we now, and where should we go?
PrEP Pre-Exposure Prophylaxis
Percolating HIV Px Pipeline
MTN-037 Protocol Overview
AIDSACTIONBALTIMORE PREP UP TOWN HALL
Rectal Gels for PrEP Are They an Option?
José Bauermeister PhD, MPH University of Pennsylvania MTN BRWG Member
Rectal Microbicide Protocol Status
2025 AIDS targets Technical meeting on prevention
Future Efficacy Trials for ARV-based Prevention
Joint work with Holly Janes, Peter Gilbert
Presentation transcript:

Ian McGowan MD DPhil FRCP University of Pittsburgh Pittsburgh, PA, USA Why We Need More than PrEP Expanding the HIV Prevention Toolbox in Africa Ian McGowan MD DPhil FRCP University of Pittsburgh Pittsburgh, PA, USA

Disclosure I have no financial relationships with a commercial entity producing, marketing, reselling or distributing healthcare related products and/or services.

Prevention Options for MSM & TGW Proven interventions Oral PrEP (Diagnosis and treatment of STIs) (Condoms) (Circumcision) Interventions under evaluation Long-acting antiretroviral agents Broadly neutralizing antibodies Rectal microbicides Vaccines

What Do People Want? “With a lack of understanding of their social and sexual lives and HIV risks, and with MSM being a hidden and stigmatized group in the region, optimized HIV prevention packages for southern African MSM are an urgent public health and research priority.” McNaghten A et al. 2014

The State of the Science

Rectal Microbicides

How Are They Applied?

Could a Rectal Microbicide Work? “HIV” (99mTc-SC) in Ejaculate “Microbicide”(111In-DTPA) CHARM-02 Study (Hiruy H et al. AIDS Res Hum Retroviruses 2015)

Rectal Microbicide Animal Models Humanized mouse Rhesus macaque

Rectal Microbicide Studies Completed studies Nonoxynol-9 HIVNET-008 UC781 RMP-01 Tenofovir 1% gel RMP-02/MTN-006 MTN-007 Project Gel CHARM-01 & CHARM-02 Maraviroc CHARM-03 Phase 2 MTN-017 Planned Phase 1 Studies MTN-026 MTN-033 MTN-037 MTN-039 DREAM-01 PREVENT-01

Questions to Consider Do we need rectal microbicides? Is tenofovir 1% gel the best candidate to move into later stage development? Is a vaginal applicator the best way to deliver a microbicide? What is the best dosing regimen? What is the best study design?

Priorities in Rectal Microbicide Research Pericoital use Extended efficacy (72 hours) Lubricant rather than applicator delivery Multipurpose products HIV, HPV, HSV, HCV Novel delivery systems Rectal douches Rectal inserts THSY08 The future of chemoprophylaxis: new concepts Abstract: THSY08 Thursday @ 14:30 – 16:00 Session Room 6

Long Acting Antiretroviral PrEP

Requirements for LA ARV Potency and PK profile allowing infrequent dosing (~ 2-3 months) Practical injection volume (~ 4mL) Stable formulation ideally without cold chain requirements Potential products TMC278 LA (Rilpivirine) GSK 744 (Cabotegravir)

Rilpivirine Levels in Plasma Persistence of rilpivirine following single dose of long-acting injection Abstract: TUAC0103 Tuesday @ 11:00 – 12:30 Session Room 11 1200 mg 600 mg 300 mg Jackson A et al. Clinical Pharmacology & Therapeutics 2014

HPTN-083 Study of Cabotegravir One month oral run in phase Exposure to LA PrEP every 2-3 months Two IM injections HPTN 083 is a study being done to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected men and transgender women who have sex with men (MSM and TGW). HPTN 083 will enroll approximately 4500 HIV-uninfected MSM and TGW at risk for acquiring HIV infection, ages 18 or older at sites in the Americas, Asia and South Africa. Status: Pending PrEP Cessation 12 months of Oral PrEP

Implantable Formulations Tenofovir alafenamide (TAF) implant Gunawardana M et al. Antimicrob Agents Chemother 2015 TAF biodegradable implant Van der Straten A USAID Grant In Progress

Broadly Neutralizing Antibodies

Broadly Neutralizing Antibodies HVTN 704 / HPTN-085 (The AMP Study) N = 2,700 This study will evaluate the safety and efficacy of the human monoclonal antibody (mAb) VRC-HIVMAB060-00-AB (VRC01) in preventing HIV-1 infection among men and transgender (TG) persons who have sex with men, in North and South America Timeline: March 2016 – September 2020 Participants will receive an intravenous (IV) infusion of 10 mg/kg of VRC01 over about 30 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72. Companion study HVTN 703 in women in Africa

Vaccines

Vaccine Development HVTN 702 Phase 3 study in South Africa ALVAC-HIV (Clade C) Bivalent gp120 protein subunit vaccine (Clade C) MF59 adjuvant Phase 3 study in South Africa Men and women N= 5,400 Duration 3 years Timeline: Starting in November 2016 The HVTN 702 vaccine regimen consists of two experimental vaccines: a canarypox-based vaccine called ALVAC-HIV and a bivalent gp120 protein subunit vaccine with an adjuvant that enhances the body's immune response to the vaccine. Both ALVAC-HIV (supplied by Sanofi Pasteur) and the protein subunit vaccine (supplied by GSK) have been modified from RV144 to be specific to HIV subtype C, the predominant HIV subtype in southern Africa. In addition, the protein subunit vaccine in HVTN 702 is combined with MF59 (also supplied by GSK), a different adjuvant than the one used in RV144, in the hope of generating a more robust immune response. Finally, the HVTN 702 vaccine regimen will include booster shots at the one-year mark in an effort to prolong the early protective effect observed in RV144

Product Access Timelines Development Phase Potential Access Oral PrEP Licensed Kenya South Africa Vaccines Phase 3 2021? Broadly neutralizing antibodies Phase 2 N/A Rectal microbicides 2022? LA PrEP Phase 2B/3

Summary In the short term oral PrEP will be the most accessible HIV prevention product for African MSM and TGW Financial constraints may limit access to oral PrEP A safe and effective HIV vaccine would have the biggest public health benefit The future of LA PrEP and BNabs is uncertain due to costs and complexity of delivery Pericoital products including rectal microbicides could provide a more cost effective PrEP product